Author’s response to reviews

Title: Systematic characterization of germline variants from the DiscovEHR study Endometrial Carcinoma population

Authors:

Jason Miller (mijason@pennmedicine.upenn.edu)
Raghu Metpally (rmetpally@geisinger.edu)
Thomas Person (tnperson@geisinger.edu)
Sarathbabu Krishnamurthy (sbkrishnamurthy@geisinger.edu)
Venkata Ramesh Dasari (vrdasari@geisinger.edu)
Manu Shivkumar (mkshivakumar@geisinger.edu)
Daniel Lavage (drl5070@yahoo.com)
Adam M Cook (amcook1@geisinger.edu)
David Carey (djcarey@geisinger.edu)
Marylyn Ritchie (marylyn@pennmedicine.upenn.edu)
Dokyoon Kim (dkim@geisinger.edu)
Radhika Gogoi (radhika.gogoi@gmail.com;rpgogoi@geisinger.edu)

Version: 3 Date: 12 Apr 2019

Author’s response to reviews:

Response to the editor:

------------------------------------------------------------------------

Thank you for the comments and suggestions with respect to our manuscript. Below you will find a point by point descriptions of our corrections and edits.
1. Please include the full name of the ethics committee (and the institute to which it belongs) that approved the study and the committee’s reference number if appropriate.

The ethics committee and the reference number have now been added.

2. Please confirm whether informed consent, written or verbal, was obtained from all participants and clearly state this in your "Ethics and Consent to Participate" section. If verbal, please state the reason and whether the ethics committee approved this procedure. If the need for consent was waived by an ethics committee or is deemed unnecessary according to national regulations, please clearly state this, including the name of the committee or a reference to the relevant legislation.

We have added the following to the ethics statement in order to clarify how the study was performed:

"The DiscovEHR cohort enrolled individuals from MyCode, which uses written consent and has previously been described (Carey DJ, et al., 2016). This study was deemed to be exempt, therefore no further consent was needed. Geisinger Medical Ethics Committee – Geisinger Health System IRB protocol. “Phenotype validation and Biomarker Discovery Protocol for gynecological disorders”. IRB number 2016-0119 was approved on 03/10/2016. "


3. Please ensure that all figures/tables and supplementary files are cited within the text. Any items which are not cited may be deleted by our production department upon publication. Currently figure 3 does not appear to be cited in the main text.

We have gone through the manuscript and made sure all figures and tables are cited in the text.
4. Thank you for providing your tracked changes document. However, at this stage it is not required and so we kindly ask that you remove it from your manuscript.

All comments and track changes have been removed.